**CLAIMS**

1. Use of a pharmaceutical composition, wherein said pharmaceutical composition reduces the expression of MMP12 and MMP13, in the manufacture of a medicament for the treatment of acne vulgaris in a subject in need thereof, wherein the pharmaceutical composition comprises from 1 µg/g to 100 µg /g of a pharmaceutical agent comprising a retinoic acid receptor agonist, and wherein the said medicament is to be administered.

2. The use according to claim 1, wherein the agent comprises a retinoic acid receptor agonist and a pharmaceutically acceptable carrier, wherein the retinoic acid receptor agonist comprises a γ- retinoic acid receptor agonist.

3. The use according to claim 1 or claim 2, wherein the pharmaceutical composition is to be administered once daily, twice daily, once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.

4. The use according to any of the preceding claims, wherein the pharmaceutical composition is formulated as a cream or as an oil-in-water emulsion.

5. The use according to any of the preceding claims, wherein the acne vulgaris is acne vulgaris of the face or trunk.

6. The use according to any of the preceding claims, wherein the acne vulgaris comprises mild, moderate and severe acne vulgaris.

7. The use according to any of the preceding claims, wherein the pharmaceutical composition is to be topically administered to the area of the subject affected with acne vulgaris.

8. The use of claim 2, wherein the γ- retinoic acid receptor agonist is trifarotene.

9. Use of a pharmaceutical composition for monitoring or determining the efficacy of a treatment of acne with a pharmaceutical composition comprising a retinoid in a subject, the method comprising:

(a) determining the level of expression of MMP12 and MMP13 in a control biological sample of said subject to obtain an expression value;

(b) repeating step (a) to obtain expression values of MMP12 and MMP13, for a test biological sample obtained after the initiation of treatment with a pharmaceutical composition comprising a retinoid; and

(c) calculating the change in said expression values of MMP12 and MMP13 between the control biological sample and the test biological sample;

wherein a decrease in the expression of MMP12 and MMP13 in the test sample relative to the control sample indicates that said subject exhibits a beneficial response to said treatment; thereby monitoring or determining the efficacy of a treatment with a therapeutic agent and the disease progression.

10. The use according to claim 9, wherein the biological sample comprises a skin biopsy.

11. The use according to claim 10, wherein the skin biopsy comprises papule biopsy.

12. The use according to claim 9, wherein the acne comprises acne vulgaris.

13. The use according to claim 9, wherein the acne comprises acne vulgaris of the face or trunk.

14. The use according to claim 12 or claim 13, wherein the acne vulgaris comprises mild, moderate, and severe acne vulgaris.

15. The use according to according to any one of claims 9 to 14, wherein the pharmaceutical composition is administered once daily, twice daily, once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.

16. The use according to any one of claims 9 to 15, wherein the retinoid comprises a retinoic acid or a retinoic acid receptor agonist.

17. The use according to claim 16, wherein the retinoic acid receptor agonist is trifarotene.